Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016.

For the first time, our study showed that the reimbursement of S-1 significantly changed the chemotherapeutic treatment pattern in clinical practice, and demonstrated a significant trend for improvement in the survival outcome of patients with mPC in 2010–2016 based on four institutes across Taiwan.

also in 9,775 other papers

Increases of the adjusted AAPC in the 6-, 12-, and 24-month survival rates of the trend 2 and trend 3 study periods were observed; however, the changes in the AAPC did not reach statistical significance.

also in 111,027 other papers